Logo of jexpmedHomeThe Rockefeller University PressThis articleEditorsContactInstructions for AuthorsThis issue
J Exp Med. Aug 27, 2012; 209(9): 1595–1609.
PMCID: PMC3428945

IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cells

Abstract

Although very high levels of interleukin (IL)-1β are present in the intestines of patients suffering from inflammatory bowel diseases (IBD), little is known about the contribution of IL-1β to intestinal pathology. Here, we used two complementary models of chronic intestinal inflammation to address the role of IL-1β in driving innate and adaptive pathology in the intestine. We show that IL-1β promotes innate immune pathology in Helicobacter hepaticus–triggered intestinal inflammation by augmenting the recruitment of granulocytes and the accumulation and activation of innate lymphoid cells (ILCs). Using a T cell transfer colitis model, we demonstrate a key role for T cell–specific IL-1 receptor (IL-1R) signals in the accumulation and survival of pathogenic CD4+ T cells in the colon. Furthermore, we show that IL-1β promotes Th17 responses from CD4+ T cells and ILCs in the intestine, and we describe synergistic interactions between IL-1β and IL-23 signals that sustain innate and adaptive inflammatory responses in the gut. These data identify multiple mechanisms through which IL-1β promotes intestinal pathology and suggest that targeting IL-1β may represent a useful therapeutic approach in IBD.

Inflammatory bowel disease (IBD), clinically comprising Crohn’s disease (CD), and ulcerative colitis (UC) are chronic inflammatory disorders of the gut with complex etiologies (Kaser et al., 2010). The understanding of pathogenic mechanisms underlying the development of IBD has aided the development of novel biological therapies. Agents that block the TNF pathways have been particularly successful in IBD therapy (Melmed and Targan, 2010). However, a large proportion of patients either fail to respond or develop tolerance to TNF therapy, highlighting the need for new therapeutic targets (Baumgart and Sandborn, 2007).

IL-1β is a proinflammatory cytokine with a wide range of systemic and local effects. Primarily produced by innate leukocytes, IL-1β can modulate the function of both immune and nonimmune cells. Stimulation with IL-1β promotes the activation and effector functions of dendritic cells, macrophages, and neutrophils (Dinarello, 1996). Moreover, IL-1β can induce neutrophilia and promote neutrophil migration (Dinarello, 2009). IL-1β promotes T cell activation and survival (Ben-Sasson et al., 2009) and has recently been shown to act in concert with other proinflammatory cytokines to promote the differentiation of CD4+ Th17 cells (Sutton et al., 2006, 2009; Acosta-Rodriguez et al., 2007; Chung et al., 2009). The potent inflammatory activity of IL-1β is reflected by the tight mechanisms in place to regulate its secretion. IL-1β is translated as an inactive 31 kD precursor (pro-IL-1β) after TLR stimulation, which is cleaved into its activated 17 kD form by caspase-1, also known as interleukin-1β converting enzyme (ICE; Thornberry et al., 1992). Activation of caspase-1 relies on the formation of a multimolecular scaffold known as the inflammasome, which is triggered by the activation of intracellular NOD-like receptors (NLR) by endogenous or exogenous danger signals (Martinon et al., 2009). Upon secretion into the extracellular space, IL-1β binds and signals via the IL-1 receptor 1 (IL-1R1), which is expressed on a wide range of cell types, including epithelial and endothelial cells, hepatocytes, and innate and adaptive leukocytes (Sims and Smith, 2010). Regulatory mechanisms downstream of IL-1β secretion are also in place to limit the action of IL-1β, including the production of a natural antagonist for its receptor, IL-1RA, and the expression of a decoy receptor, IL-1R2 (Dinarello, 1996).

Several clinical studies have reported high levels of IL-1β secretion by colon lamina propria monocytes from patients with active IBD (Satsangi et al., 1987; Mahida et al., 1989; Ligumsky et al., 1990; Reinecker et al., 1993; McAlindon et al., 1998). IL-1β levels in the colon correlated with disease activity and high levels of IL-1β were associated with active lesions (Casini-Raggi et al., 1995; Ludwiczek et al., 2004), suggesting an important role of this cytokine in promoting localized inflammation. High levels of colonic IL-1β are also a feature of many animal models of colitis (Cominelli et al., 1990; Okayasu et al., 1990; McCall et al., 1994), and treatment with IL-1–blocking agents has been successful in ameliorating acute models of intestinal injury and inflammation (Thomas et al., 1991; Cominelli et al., 1992; Siegmund et al., 2001). Furthermore, different genetic lesions associated with IBD development in animal models are associated with increased IL-1β. For example, macrophages from knock-in mice bearing the most common CD-associated variant of the Nod2 gene produced high levels of IL-1β after stimulation with muramyl dipeptide (MDP; Maeda et al., 2005). These NOD2 mutant mice also developed exacerbated disease in response to acute dextran sulfate sodium (DSS)–induced intestinal injury, which was significantly ameliorated by the administration of recombinant IL-1RA (Maeda et al., 2005). In addition, conditional deletion of the CD-linked autophagy gene Atg16l1 in the hematopoietic system of mice resulted in increased IL-1β production after LPS stimulation and increased susceptibility to DSS-mediated intestinal injury, a phenotype reversed by co-treatment with αIL-18 and αIL-1β antibodies (Saitoh et al., 2008). The importance of IL-1β in modulating intestinal inflammation has been confirmed by infection studies, as blocking IL-1β ameliorated inflammatory pathology in both Clostridium difficile–associated colitis and Salmonella typhimurium–induced enteritis (Müller et al., 2009; Ng et al., 2010).

Although IL-1β has been linked to Th17 cell responses, the role of IL-17A in the development of intestinal inflammation is controversial. In acute models of intestinal injury, IL-17A plays a disease protective role, with Il17a−/− mice showing increased pathology and leukocyte infiltration after DSS administration (Ogawa et al., 2004). However, studies in chronic inflammatory models have highlighted a more complex role for IL-17A. Studies from our laboratory demonstrated a pathogenic role for IL-17A in Helicobacter hepaticus (H. hepaticus)–driven innate immune IBD (Buonocore et al., 2010). Similarly, administration of an αIL-17A antibody ameliorated the spontaneous colitis developed by mice bearing a conditional deletion of the transcription factor Stat3 in regulatory Foxp3+ T cells (Chaudhry et al., 2009). Th17 cells are enriched in the inflamed gut both in animal models and in humans (Fujino et al., 2003; Nielsen et al., 2003; Hue et al., 2006; Kullberg et al., 2006) and T cells lacking the transcription factor RORγ, that directs Th17 differentiation, could not transfer colitis to C57BL/6 Rag1−/− mice (Leppkes et al., 2009). However, T cell–derived IL-17A is not absolutely required for the development of intestinal pathology in T cell transfer models of colitis and it has been proposed that T cell–derived IL-17A and IL-17F might play a redundant role in driving intestinal inflammation (Izcue et al., 2008; Leppkes et al., 2009; O’Connor et al., 2009). These conflicting results might be explained by an as yet undiscovered additional pathogenic function of Th17 cells. Alternatively, a complex network of proinflammatory cells may contribute to IL-17A–mediated pathology in vivo (Littman and Rudensky, 2010).

In this study, we aimed to assess the role of IL-1β in chronic intestinal inflammation. As a result of the pluripotent activity of IL-1β, we used complementary animal models of chronic colitis to selectively analyze the effects of IL-1β on adaptive and innate immune-mediated intestinal inflammation. Our results show that IL-1β signals are required for the development of severe inflammation in both T cell–independent and T cell–mediated colitis. Moreover, we identified key mechanisms underlying the pathogenic function of IL-1β, including a central role for this cytokine in promoting the accumulation of IL-17A–producing innate and adaptive immune cells.

RESULTS

IL-1β plays a key role in innate intestinal inflammation

To specifically analyze the role of IL-1β in modulating innate inflammatory responses in the intestine, we infected T cell– and B cell–deficient 129SvEv Rag2−/− mice with H. hepaticus, which results in the development of colonic and cecal inflammation that is entirely dependent on innate immunity (Erdman et al., 2003; Maloy et al., 2003). We first examined whether H. hepaticus–induced intestinal inflammation was associated with increased levels of active IL-1β by analyzing the levels of IL-1β secretion by organ explants from the gastrointestinal tract of H. hepaticus–infected 129SvEv Rag2−/− mice. Intestinal inflammation in the colon and cecum of H. hepaticus–infected 129SvEv Rag2−/− mice was associated with high levels of secreted IL-1β (Fig. 1 A). In contrast, no increase in IL-1β levels was observed in the ileum of H. hepaticus–infected 129SvEv Rag2−/− mice (Fig. 1 A). Given that both colonization and H. hepaticus–induced inflammation occur primarily in the colon and cecum, this result suggests that IL-1β secretion is directly linked to local intestinal inflammation. Innate leukocytes appear to be the major source of IL-1β secretion in the lamina propria in IBD patients (Mahida et al., 1989; McAlindon et al., 1998). We observed high levels of IL-1β secretion by purified colonic lamina propria leukocytes (cLPLs) of H. hepaticus–infected 129SvEv Rag2−/− mice (Fig. 1 B), confirming that chronic intestinal inflammation correlates with increased local secretion of IL-1β by innate leukocytes.

Figure 1.
H. hepaticus–induced innate immune driven typhlocolitis is associated with IL-1β secretion. 129SvEv Rag2−/− mice were infected with H. hepaticus and sacrificed >8 wk after infection. (A) IL-1β secretion ...

To formally assess the requirement for IL-1β in H. hepaticus–induced innate intestinal inflammation, we blocked the activity of IL-1β with a neutralizing monoclonal antibody (αIL-1β). Treatment of H. hepaticus–infected 129SvEv Rag2−/− mice with αIL-1β resulted in significant attenuation of colitis (Fig. 2, A–C), without affecting H. hepaticus colonization (unpublished data). Although cecal inflammation was not significantly attenuated (not depicted), hepatic inflammation was also reduced by administration of αIL-1β, as illustrated by the decreased number of inflammatory foci (Fig. 2 C). Moreover, systemic inflammation was also reduced after IL-1β blockade, as shown by decreased splenomegaly and spleen cellularity in αIL-1β–treated animals (Fig. 2 B). These results identify a role for IL-1β in promoting intestinal and systemic innate inflammation after H. hepaticus infection. To further characterize the effect of blocking IL-1β, we examined the levels of proinflammatory cytokines secreted by purified cLPLs from the different treatment groups (Fig. 2 D). As expected (Hue et al., 2006), we observed an increase in proinflammatory cytokine production by cLPLs from H. hepaticus–infected colitic mice. After administration of αIL-1β, we observed significantly decreased levels of IL-6, IFN-γ, IL-17A, and IL-1β when compared with isotype control–treated animals (Fig. 2 D). In addition, significantly increased levels of IL-6 were detected in the serum of H. hepaticus–infected animals, and these were markedly reduced by αIL-1β treatment (Fig. 2 E). These results support a crucial role of IL-1β in promoting proinflammatory cytokine cascades in innate immune colitis.

Figure 2.
IL-1β drives innate immune colitis. 129SvEv Rag2−/− mice were infected with H. hepaticus, treated weekly with 1 mg of αIL-1β antibody or isotype control (i.p.), and sacrificed after 8 wk of infection. (A) Scores ...

IL-1β blockade decreases granulocyte recruitment and accumulation of IL-17A–producing innate lymphoid cells in the colon

H. hepaticus–induced innate colitis is associated with pronounced accumulation of proinflammatory CD11b+Gr1Hi granulocytes in the colon and spleen of infected mice (Hue et al., 2006). Thus, we isolated leukocytes from different tissues of H. hepaticus–infected αIL-1β–treated and isotype control-treated 129SvEv Rag2−/− mice and analyzed the frequency of granulocytes by flow cytometry. As expected, H. hepaticus–mediated inflammation was associated with an increase in the frequency of CD11b+Gr1Hi cells in the colon and spleen (Fig. 3, A and B). Blocking IL-1β in H. hepaticus–infected 129SvEv Rag2−/− resulted in a decrease in the frequency of CD11b+Gr1Hi granulocytes in the colon, although it did not affect frequencies in the spleen (Fig. 3, A and B). IL-1β promotes neutrophil recruitment by inducing the expression of C-X-C chemokines in vivo (Calkins et al., 2002). Accordingly, we observed a significant down-regulation of Cxcl1 (KC), Cxcl2 (MIP2α), and Cxcl5 (ENA78) in the colon of H. hepaticus–infected 129SvEv Rag2−/− mice treated with αIL-1β, compared with H. hepaticus–infected mice receiving an isotype control (Fig. 3 C). These data highlight an intestine-specific role of IL-1β in promoting the recruitment of proinflammatory innate immune cell populations through the induction of chemokine expression.

Figure 3.
Blocking IL-1β impairs the accumulation of proinflammatory CD11b+Gr1Hi granulocytes in the inflamed colon. 129SvEv Rag2−/− mice were infected with H. hepaticus, treated weekly with 1 mg of αIL-1β antibody or isotype ...

We recently identified a novel population of Rorγt+ Sca1+ Thy1.2Hi innate lymphoid cells (ILCs) that play an important role in innate immune-mediated intestinal inflammation (Buonocore et al., 2010). Expression analysis revealed that ILCs isolated from the large intestine of H. hepaticus–infected 129SvEv Rag2−/− mice express high levels of the IL-1 receptor IL-1R1 (Fig. 4 A), suggesting that ILCs can directly be modulated by IL-1β in vivo. Thus, we analyzed the number and function of these cells in the colon after αIL-1β treatment compared with isotype control–treated mice. We observed significantly decreased numbers of ILCs in the colons of H. hepaticus–infected 129SvEv Rag2−/− mice that received αIL-1β compared with those treated with an isotype control (Fig. 4 B). During H. hepaticus–induced intestinal inflammation, ILCs produce the proinflammatory cytokines IL-17A and IFN-γ, and these responses are enhanced after stimulation with IL-23 (Buonocore et al., 2010). Intracellular cytokine staining revealed that the observed decrease in ILC number in the colon after αIL-1β treatment was accompanied by a significant decrease in IL-17A–producing ILCs and by a reduction in the number of IFN-γ–producing ILCs (Fig. 4 C). These results indicate a role of IL-1β in promoting the accumulation and activation of ILCs in the colon. As we have shown that ILCs are the major IL-23–responsive population in this innate colitis model (Buonocore et al., 2010), we cultured cLPLs from αIL-1β–treated, H. hepaticus–infected 129SvEv Rag2−/− mice in the presence of IL-23. Blockade of IL-1β in vivo resulted in decreased production of both IL-17A and IFN-γ by IL-23–stimulated cLPLs in vitro (Fig. 4 D). Consistent with this reduced response to IL-23, cLPLs isolated from αIL-1β–treated H. hepaticus–infected 129SvEv Rag2−/− exhibited reduced IL23r expression compared with those isolated from mice receiving an isotype control (Fig. 4 E). To test whether IL-1β directly regulated IL23r expression by ILCs, FACS sorted ILCs from the large intestines of H. hepaticus–infected 129SvEv Rag2−/− mice were cultured with IL-1β and IL23r expression assayed using qRT-PCR. ILCs that were cultured with IL-1β expressed higher levels of IL23r than those cultured in medium alone, whereas the levels of expression of the transcription factor Rorγt did not change upon culture with IL-1β (Fig. 4 F). Conversely, culture with IL-23 did not significantly enhance Il1r1 expression by ILCs (Fig. 4 G). Collectively, these data indicate that IL-1β plays multiple roles in promoting innate immune responses in the colon by modulating recruitment, accumulation, and function of key proinflammatory cell types.

Figure 4.
αIL-1β treatment reduces the accumulation of IL-17A–producing ILCs in the colon. (A) IL-1R1 expression by Sca1+Thy1.2Hi ILCs and rest of large intestine lamina propria cells. 129SvEv Rag2−/− mice were infected with ...

T cell–specific IL-1R1 signaling drives T cell–mediated intestinal inflammation

We next addressed whether IL-1β could also promote deleterious adaptive immune responses within the intestine. To this end, we used the T cell transfer model of colitis in which transfer of naive CD4+ T cells to a lymphopenic host results in rapid colitis and systemic cachexia (Powrie et al., 1993). Intestinal inflammation in this model of colitis was associated with increased levels of IL-1β secretion by cLPLs (Fig. 5 A). To assess the requirement for IL-1β stimulation of T cells in intestinal inflammation, we transferred naive CD4+CD45RBHi T cells isolated from either WT or Il1r1−/− mice into C57BL/6 Rag1−/− recipients and assessed the development of pathology. As expected, adoptively transferred WT naive CD4+ T cells induced weight loss and severe intestinal and systemic inflammation in C57BL/6 Rag1−/− recipients (Fig. 5, B–F). In contrast, Il1r1−/− naive CD4+ T cells failed to induce weight loss upon transfer to C57BL/6 Rag1−/− mice compared with recipients of WT naive CD4+ T cells (Fig. 5 B). Moreover C57BL/6 Rag1−/− mice transferred with Il1r1−/− naive CD4+ T cells showed significantly reduced intestinal pathology in both the cecum and the colon (Fig. 5, C–E). Despite attenuated intestinal inflammation, no significant difference was observed in either splenomegaly or spleen cellularity in C57BL/6 Rag1−/− mice receiving WT or Il1r1−/− naive CD4+ T cells (Fig. 5 F). The attenuated intestinal inflammation in the colon of C57BL/6 Rag1−/− mice receiving Il1r1−/− naive CD4+ T cells was accompanied by significant reductions in secretion of the proinflammatory cytokines IL-6, IFN-γ, TNF and IL-17A by cLPLs (Fig. 5 G), indicating a general dampening of the intestinal inflammatory response in the absence of IL-1R signaling on T cells.

Figure 5.
T cell–driven intestinal inflammation is attenuated in the absence of IL-1R signaling. (A) C57BL/6 Rag1−/− mice were transferred with 4 × 105 CD4+ CD25 CD45RBHi T cells from C57BL/6 WT mice and culled at the development ...

IL-1R1 signaling promotes accumulation and survival of Th17 cells in the colon

We next analyzed the effects of cell-specific IL-1R signals on the accumulation of CD4+ T cells in the colon. When compared with recipients of WT naive CD4+ T cells, C57BL/6 Rag1−/− mice that received Il1r1−/− naive CD4+ T cells exhibited a 50% decrease in the number of CD4+ T cells present in the colon (Fig. 6 A), suggesting that IL-1R expression by T cells is essential to drive their accumulation in the intestine. Moreover, the effect of IL-1R signaling on accumulation of CD4+ T cells was specific to the intestine, because similar CD4+ T cell numbers were found in the MLN or spleen of C57BL/6 Rag1−/− mice receiving WT or Il1r1−/− naive CD4+ T cells (Fig. 6 A).

Figure 6.
Impaired Th17 accumulation in the gut in the absence of IL-1R1 signaling. (A) C57BL/6 Rag1−/− mice were transferred with 4 × 105 CD4+ CD25 CD45RBHi T cells from C57BL/6 WT or Il1r1−/− mice. At sacrifice, ...

The T cell transfer model of colitis is characterized by accumulation of Th1 and Th17 cells in the colon (Hue et al., 2006; Izcue et al., 2006). Recently, it has been proposed that IL-1β plays a key role in promoting the differentiation of Th17 cells (Sutton et al., 2006; Chung et al., 2009; Sutton et al., 2009). In agreement with these findings, we found that after in vitro culture with TGF-β and IL-6, Il1r1−/− T cells exhibited decreased differentiation into Th17 cells when compared with WT CD4+ T cells (Fig. 6 B). To assess the role of IL-1R expression on T helper cell differentiation in vivo, we isolated CD4+ T cells from the colon of C57BL/6 Rag1−/− mice receiving WT or Il1r1−/− naive CD4+ T cells and performed intracellular staining for IL-17A and IFN-γ production. We found that IL-1R expression was dispensable for Th1 and Th17 cell differentiation in the colon, as shown by similar frequencies of these effector cells observed in recipients of WT or Il1r1−/− naive CD4+ T cells (Fig. 6 C). IL-1R expression was also dispensable for Th17 differentiation in the MLN (not depicted). Furthermore, we observed similar numbers of CD4+ IL-17AIFN-γ+ Th1 cells and IL-17A+IFN-γ+ T cells in the colon of C57BL/6 Rag1−/− mice receiving Il1r1−/− or WT naive CD4+ T cells (Fig. 6 D). In contrast, we observed a specific defect in the accumulation of IL-17A–producing CD4+ T cells, as shown by a 50% decrease in the number of IL-17A+ IFN-γ T cells found in the colon of C57BL/6 Rag1−/− mice receiving Il1r1−/− naive CD4+ T cells when compared with recipients of WT naive CD4+ T cells (Fig. 6 D). To further examine the role of IL-1R1 signaling on T cell effector functions, we isolated CD4+ T cells from the colon of mice transferred either with WT or Il1r1−/− naive CD4+ T cells and examined their cytokine profile ex vivo. In accordance with our previous data, colonic Il1r1−/− CD4+ T cells secreted less IL-17A, whereas the levels of IFN-γ secretion were unaffected (Fig. 6 E). Together, these data indicate a role for T cell–specific IL-1R1 signaling in promoting the accumulation of CD4+ T cells in the colon, with a specific defect in Th17 cells.

Recent reports show that IL-1β promotes GM-CSF production by Th17 cells, and that GM-CSF plays a key role in development of experimental autoimmune encephalomyelitis (EAE; Codarri et al., 2011; El-Behi et al., 2011). We found that colonic Il1r1−/− CD4+ T cells isolated after T cell transfer secreted significantly less GM-CSF than colonic WT CD4+ T cells (Fig. 6 E), prompting us to assess the role of T cell–derived GM-CSF in promoting intestinal inflammation. To this purpose, we adoptively transferred GM-CSF–deficient (csf2−/−) naive CD4+CD45RBHi T cells to C57BL/6 Rag1−/− mice. We observed that the level of colonic inflammation was similar between mice receiving WT or csf2−/− naive CD4+ T cells (Fig. 6 F). Cecal inflammation and splenomegaly were also unaffected by the inability of naive T cells to produce GM-CSF, and the proportions and numbers of IL-17A+IFN-γ, IL-17A+IFN-γ+ and IL-17AIFN-γ+ effector CD4+ T cells were similar in recipients of csf2−/− and WT naive T cells (unpublished data). These data indicate that T cell–derived GM-CSF is not required to induce intestinal inflammation or to facilitate Th17 cell differentiation in the gut.

Next, we examined whether the defective accumulation of Th17 cells in the absence of cell-specific IL-1R expression could be caused by defective proliferation of the Il1r1−/− T cells in the colon. However, CD4+ T cells and Th17 cells isolated from the colon of C57BL/6 Rag1−/− mice receiving Il1r1−/− or WT naive CD4+ T cells expressed the proliferation marker Ki67 to a similar extent (Fig. 7 A). Moreover, adoptive transfer of CFSE-labeled Il1r1−/− or WT naive T cells revealed similar CFSE dilution profiles 12 d after transfer (unpublished data), suggesting that Il1r1−/− T cells undergo comparable early expansion after adoptive transfer. Alternatively, we hypothesized that the absence of IL-1R signals could compromise the ability of CD4+ T cells to migrate to the colon. To test this hypothesis, we transferred Il1r1−/− or WT CD4+CD45RBHi T cells into C57BL/6 Rag1−/− mice and sacrificed them 2 wk after transfer, before the onset of colitis. At this early time point, no difference in the total number of CD4+ T cells or Th17 cells present in the colon was observed between C57BL/6 Rag1−/− mice receiving Il1r1−/− or WT naive CD4+ T cells (Fig. 7 B). Moreover, Ki67 expression by total CD4+ T cells or by Th17 cells was again comparable in WT and Il1r1−/− CD4+ T cells (unpublished data). In addition, Il1r1−/− CD4+ T cells exhibited comparable expression of the chemokine receptors Ccr6, Ccr2, Ccr5, and Cxcr6 (Fig. 7 C). Together, these results excluded an effect of IL-1R expression in preventing T cell migration to the colon or in impairing early T cell proliferation.

Figure 7.
IL-1R signaling modulates CD4+ T cell apoptosis in vivo and in vitro. (A) C57BL/6 Rag1−/− mice were transferred with 4 × 105 CD4+ CD25 CD45RBHi T cells from C57BL/6 WT or Il1r1−/− mice. At sacrifice, cLPLs ...

We therefore hypothesized that the defective accumulation of naive Il1r1−/− CD4+ T cells could be caused by impaired survival. To assess this point, we first tried to quantify apoptotic T cells in vivo by staining colonic sections from colitic mice by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) or caspase-3 staining combined with αCD3 immunofluorescence staining. However, the frequency of CD3+ apoptotic cells in these assays was too low to allow accurate quantification of apoptotic events, probably reflecting the rapid clearance of apoptotic cells in vivo (unpublished data). Therefore, we FACS sorted CD4+ T cells from the colon of C57BL/6 Rag1−/− mice receiving either WT or Il1r1−/− naive CD4+ T cells and assessed the expression of the antiapoptotic factors Bcl2 and Bclxl by qRT-PCR. Our analysis showed that colonic CD4+ T cells from mice receiving Il1r1−/− naive CD4+ T cells expressed significantly lower levels of Bcl2 and Bclxl compared with those from mice transferred with WT naive CD4+ T cells (Fig. 7 D). Furthermore, Il1r1−/− CD4+ T cells exhibited significantly higher levels of apoptosis than WT CD4+ T cells after stimulation with αCD3 and αCD28 mAb in vitro (Fig. 7 E), supporting the hypothesis that IL-1R1 signaling promotes T cell survival during inflammation, by preventing activation-induced apoptosis. In contrast, stimulation of freshly isolated ILCs with IL-1β did not affect their expression of Bcl2 (Fig. 7 F).

T cell–specific IL-23R signals are also required for intestinal inflammation, as Il23r−/− naive CD4+ T cells failed to induce intestinal pathology upon T cell transfer to C57BL/6 Rag−/− mice (Ahern et al., 2010). Initially, we hypothesized that, similar to ILCs, T cells required Il1r1 signals to up-regulate Il23r expression. However, FACS sorted CD4+ T cells from the colon of mice transferred with either WT or Il1r1−/− naive CD4+ T cells expressed similar levels of IL-23R (Fig. 8 A). Because it has been reported that IL-1R1 expression is up-regulated in Th17 cells (Chung et al., 2009), we conjectured that in the colon this might be driven by IL-23, which is key for the generation of colitogenic CD4+ T cell responses (Ahern et al., 2010). To test this hypothesis, we co-transferred equal numbers of CD45.1+ WT and CD45.2+ Il23r−/− naive CD4+ T cells into C57BL/6 Rag−/− recipients and, after the development of colitis, we isolated colonic WT and Il23r−/− CD4+ T cells by FACS sorting based on the expression of CD45.2. This strategy allows comparison of Il23r−/− and WT CD4+ T cells that have been conditioned in an identical inflamed intestinal environment (Ahern et al., 2010). Analysis by qRT-PCR revealed that colonic Il23r−/− CD4+ T cells expressed significantly lower levels of IL1r1 than colonic WT CD4+ T cells (Fig. 8 B), suggesting that T cell–specific IL-23R signals promoted increased sensitivity to IL-1 in vivo. However, the levels of expression of the Th17 signature transcription factor Rorc were similar between the two groups, suggesting that the observed reduction of IL-1R expression is not caused by a general impairment of Th17 differentiation in vivo (Fig. 8 B). Consistent with this hypothesis, Il23r−/− naive CD4+ T cells failed to up-regulate IL1r1 when cultured under Th17 polarizing conditions (including IL-23) in vitro, whereas WT naive CD4+ T cells demonstrated a marked increase in IL1r1 expression over the culture period (Fig. 8 C). Together, these data suggest that IL-23 signaling on T cells promotes IL-1R expression, thereby enhancing T cell sensitivity to IL-1.

Figure 8.
IL-1R1 expression by colonic CD4+ T cells is dependent on IL-23 stimulation. (A) C57BL/6 Rag1−/− mice were transferred with 4 × 105 CD4+ CD25 CD45RBHi T cells from C57BL/6 WT or Il1r1−/− mice. Mice were ...

DISCUSSION

Numerous studies link intestinal inflammation in IBD patients with increased intestinal levels of IL-1β. However, a lack of preclinical research into the role of IL-1β in promoting chronic intestinal inflammation has hampered the translation of these clinical observations into potential therapeutic strategies, in spite of new evidence in humans linking dysregulated IL-1β secretion with polymorphisms associated to IBD development (Plantinga et al., 2011). Here, using two complementary models of intestinal inflammation, we have dissected the cellular mechanisms through which IL-1β contributes to intestinal pathology. We found that IL-1β was essential for the development of severe innate immune pathology driven by the intestinal pathogen H. hepaticus. We identified an intestine-specific role for IL-1β in driving classical pathways of innate immune inflammation, by promoting the recruitment of granulocytes to the colon. In addition, we showed that IL-1β stimulation of CD4+ T cells was required for the induction of intestinal inflammation in a T cell transfer model of colitis by promoting the accumulation and survival of CD4+ T cells in the colon. Moreover, we observed a crucial role for IL-1β in inducing “type-17” responses from both innate and adaptive leukocytes in the colon.

Using a T cell–independent model of colitis, we assessed the role of IL-1β in driving innate intestinal inflammation. In accordance with the central role played by IL-1β in orchestrating innate inflammatory responses (Dinarello, 1996; Sims and Smith, 2010), we observed attenuation of H. hepaticus–induced colitis after αIL-1β treatment. The common adaptor protein, MyD88, is responsible for signaling downstream of the IL-1R (Dinarello, 2009) and previous studies from our laboratory showed MyD88−/− mice to be completely protected from H. hepaticus–induced colitis (Asquith et al., 2010). Interestingly, H. hepaticus–infected MyD88−/− mice were completely protected from typhlocolitis, whereas only colitis was significantly decreased in αIL-1β–treated mice, implying that IL-1β contributes mainly to proinflammatory MyD88-dependent signals in the colon. Consistent with this hypothesis, H. hepaticus–infected 129SvEv Rag2−/− mice treated with αIL-1β exhibited a selective decrease in neutrophil recruitment in the colon. Others have reported that blocking the IL-1β pathway ameliorated DSS-triggered intestinal inflammation (Thomas et al., 1991; Cominelli et al., 1992; Siegmund et al., 2001). IL-1R deficiency in these models did not perturb granulocyte recruitment to the colon. However, DSS colitis represents an acute model of colitis where granulocyte recruitment is secondary to the extensive epithelial damage caused by the initial bacterial or chemical injury. In contrast, H. hepaticus–induced intestinal pathology in 129SvEv Rag2−/− mice is primarily associated with chronic activation of innate leukocytes in the lamina propria (Asquith and Powrie, 2010; Asquith et al., 2010). Hence the mechanisms underlying intestinal pathology and leukocyte recruitment are profoundly different between these models of colitis.

Our data show that IL-1β acts to boost IL-17A production in the intestine of H. hepaticus–infected 129SvEv Rag2−/− mice. Given that IL-17A production contributes to pathology in this model (Buonocore et al., 2010), it is possible that the decreased inflammation observed after treatment with αIL-1β is due, at least in part, to its effects on IL-17A. We further observed that IL-1β was required for the accumulation of a novel population of IL-17A–producing ILCs, which express high levels of IL-1R1. Fewer numbers of Sca1+ Thy1.2Hi ILCs were present in the colon of H. hepaticus–infected 129SvEv Rag2−/− mice receiving αIL-1β compared with those treated with an isotype control. In addition, ILCs isolated from the colon of H. hepaticus–infected 129SvEv Rag2−/− mice that were treated with αIL-1β had reduced frequencies of IL-17A– and IFN-γ–secreting cells, which correlated with decreased secretion of these cytokines in response to IL-23 stimulation. Thus, IL-1β signals promote the accumulation and effector functions of ILCs in the intestine. A role for IL-1β in promoting the in vitro proliferation and function of a distinct innate lymphoid cell type has been proposed. NK-22 or RORγt+CD127+ NK-like cells are present at mucosal sites and can secrete both IL-22 and IL-17A in response to IL-23 (Cella et al., 2009; Cupedo et al., 2009). Recently, it has been shown that IL-1β can strongly synergize with other cytokines, such as IL-7, IL-15, or IL-23, to promote proliferation and effector cytokine secretion by NK-22 cells in vitro (Cella et al., 2010; Hughes et al., 2010; Reynders et al., 2011). Thus, IL-1β may play a crucial role in modulating the functions of several types of innate lymphoid cells at mucosal sites. The exact mechanisms underlying these effects remain unclear, but it is possible that IL-1β acts in concert with other factors to regulate ILC function, as IL-1β stimulation alone has only minor effects on innate lymphoid cell biology (Cupedo et al., 2009; Hughes et al., 2010). In support of this hypothesis, we found that ILCs cultured with IL-1β had significantly higher levels of Il23r expression than those cultured with medium alone, suggesting that IL-1R1 signals maintain or enhance IL-23 responsiveness in ILCs.

The ability of IL-1β to promote accumulation of immune effector cells in the intestine was paralleled in our studies using a T cell–dependent colitis model. The reduced ability of Il1r1−/− naive CD4+ T cells to induce severe colitis upon transfer to C57BL/6 Rag1−/− recipients was associated with reduced accumulation of CD4+ T cells. Remarkably, the accumulation defect was restricted to the intestine, with similar numbers of CD4+ T cells found in the spleen or MLN in recipients of Il1r1−/− CD4+ T cells. This would suggest that although not required for the reconstitution of lymphopenic mice, T cell–specific IL-1R signaling is a prerequisite for T cell accumulation in the intestine. Mechanistic analysis revealed that this effect was not caused by defective proliferation or migration of Il1r1−/− T cells, suggesting a role of IL-1β in promoting T cell survival. This hypothesis was confirmed by the observation that the expression of the antiapoptotic proteins Bcl-2 and Bcl-xL was impaired in colonic Il1r1−/− CD4+ T cells after transfer to lymphopenic mice. These results are consistent with previous findings that naive MyD88−/− CD4+ T cells also exhibited impaired ability to accumulate in the intestine and mediate colitis after transfer into C57BL/6 Rag1−/− mice, associated with reduced expression of Bcl2 and Bcl-xL (Fukata et al., 2008; Tomita et al., 2008; Asquith et al., 2010). Overall, these data suggest that IL-1R/Myd88 signaling is crucial to promote T cell survival during intestinal inflammation.

Defective CD4+ T cell accumulation in the intestine after transfer of naive Il1r1−/− CD4+ T cells was primarily caused by decreased numbers of Th17 cells. Previous studies in humans and mice have identified a role for IL-1 in promoting Th17 differentiation, and autoinflammatory diseases characterized by high levels of IL-1β are associated with a marked Th17 signature at the effector site (Horai et al., 2000; Aksentijevich et al., 2009; Brydges et al., 2009; Meng et al., 2009; Reddy et al., 2009; Lamacchia et al., 2010). Additionally, in vitro studies demonstrated a clear role for IL-1β, in conjunction with the proinflammatory cytokines IL-6 and IL-23, in promoting the differentiation of Th17 cells (Sutton et al., 2006, 2009; Chung et al., 2009; Ghoreschi et al., 2010), and Il1r1−/− mice show defective Th17 differentiation in the small intestine at steady state (Shaw et al., 2012). Furthermore, T cell–specific IL-1R expression is necessary for the induction of EAE in vivo, as adoptive transfer of Il1r1−/− T cells resulted in decreased frequencies of Th17 cells in the central nervous system (Sutton et al., 2006; Chung et al., 2009). Our in vitro studies confirmed the requirement for IL-1R expression in Th17 differentiation. However, comparable frequencies of IL-17–producing CD4+ T cells were found in the colon of C57BL/6 Rag1−/− mice receiving WT or Il1r1−/− naive CD4+ T cells, which may reflect the highly polarizing Th17 microenvironment in the colon (Atarashi et al., 2008; Ivanov et al., 2009). Although dispensable for Th17 differentiation in the gut upon naive T cell transfer, IL-1R signaling was necessary to promote Th17 accumulation, as shown by the decreased numbers of Th17 cells found in the colon of C57BL/6 Rag1−/− mice receiving Il1r1−/− naive CD4+ T cells. This effect was specific to Th17 cells and was not observed for IL-17A IFN-γ+ or IL-17A+ IFN-γ+ CD4+ T cells, showing that Il1r1−/− T cells are not generally impaired in their proinflammatory capacity. This could be explained by high levels of expression of Il1r1 by Th17 cells, which may render them more sensitive to, or dependent on, IL-1R stimulation (Chung et al., 2009; Guo et al., 2009). Because proliferation and migration to the gut of Il1r1−/− naive CD4+ T cells was unimpaired, it is possible that the main function for IL-1R signals in modulating Th17 biology in the gut is to promote their survival during inflammation. This hypothesis is consistent with other studies showing that IL-1β can promote Th17 expansion and cytokine production in vitro in the absence of TCR stimulation (Sutton et al., 2006), suggesting a role of IL-1β in homeostatic maintenance of Th17 cells.

We also present evidence of synergy between IL-23R and IL-1R signals for the induction and maintenance of pathogenic Th17 responses. A previous in vitro study reported that IL-1R signaling only modestly enhanced Il23r expression by CD4+ T cells (Chung et al., 2009). Similarly, we found that colonic CD4+ T cells isolated from C57BL/6 Rag1−/− mice that received either WT or Il1r1−/− naive CD4+ T cells expressed comparable levels of Il23r. In contrast, when CD4+ T cells were isolated from the inflamed colon of C57BL/6 Rag1−/− mice that were co-transferred with both WT and Il23r−/− naive CD4+ T cells, we found that the Il23r−/− CD4+ T cells expressed significantly lower levels of Il1r1. Furthermore, Il23r−/− naive CD4+ T cells failed to increase expression of Il1r1 during culture in IL-23–supplemented, Th17-polarizing conditions in vitro. Together, these observations suggest that IL-23R signals play a key role in the up-regulation and maintenance of IL-1R expression by Th17 cells. As IL-1R signals promote T cell survival, this process establishes a positive feedback loop promoting T cell accumulation in the colon.

Recent evidence suggests that IL-1β promotes GM-CSF production by Th17 cells and that T cell–derived GM-CSF plays a key role in EAE pathology (Codarri et al., 2011; El-Behi et al., 2011). Although we found that colonic CD4+ T cells isolated from C57BL/6 Rag1−/− mice receiving Il1r1−/− CD4+ naive T cells showed reduced GM-CSF production, adoptive transfer of GM-CSF–deficient CD4+ naive T cells resulted in intestinal inflammation with similar features to that observed in C57BL/6 Rag1−/− mice receiving WT CD4+ T cells. Hence, although necessary for the development of EAE, T cell–derived GM-CSF is not required for the induction of colitis.

In summary, our data clearly show an effect of blocking IL-1β in ameliorating chronic intestinal inflammation, as well as providing mechanistic insight into the proinflammatory actions of IL-1β in the intestine. This study also highlights the synergistic activities of IL-1β and IL-23 in promoting pathogenic innate and adaptive type 17 responses in the intestine. This hypothesis is supported by the finding that IL-1β and IL-23 are expressed with similar kinetics during the development of intestinal inflammation ((Boulard et al., 2012) and unpublished data) and by previous studies showing that IL-1β and IL-23 promote a Th17-like phenotype in both CD4+ T cells and NK-22 cells in vitro (Chung et al., 2009; Cella et al., 2010; Ghoreschi et al., 2010). Numerous IL-1β–blocking reagents have been developed for clinical studies, many of which have proven successful in treating inflammatory disorders (Gabay et al., 2010). Moreover, recent data show exacerbated IL-1β production upon NOD2 stimulation of PBMCs from IBD patients bearing a risk variant of the ATG16L1 gene (Plantinga et al., 2011), confirming that IL-1β is a central effector mechanism downstream of different IBD-related inflammatory pathways. Considering the profound dysregulation of the IL-1 pathway observed in the gut of IBD patients, targeting this pathway may represent a future therapeutic approach in IBD.

MATERIALS AND METHODS

Mice.

129SvEv Rag−/−, C57BL/6, C57BL/6 Rag1−/−, C57BL/6 Il1r1−/−, and Il23r−/− C57BL/6 strains were bred and maintained under specific pathogen–free conditions in accredited animal facilities at the University of Oxford. All experiments were performed in accordance with the UK Scientific Procedures Act (1986) under a Project License (PPL) authorized by the UK Home Office Animal Procedures Committee and approved by the Sir William Dunn School of Pathology Local Ethical Review Committee. C57BL/6 csf2−/− mice were provided by B. Becher (University of Zurich, Zurich, Switzerland). Mice were routinely screened for Helicobacter spp. and were >6 wk of age when used.

Bacteria.

H. hepaticus NCI-Frederick isolate 1A, isolated from the same mouse colony as isolate Hh-1 (strain 51449; American Type Culture Collection), was grown on blood agar plates containing Trimethoprim, vancomycin, and polymixin B (Oxoid) under microaerophilic conditions, as previously described (Maloy et al., 2003; Young et al., 2004). H. hepaticus viability was confirmed using fluorescent microscopy with a bacterial live/dead kit (BacLight; Invitrogen). For induction of innate immune colitis, 129SvEv Rag2−/− mice were infected with H. hepaticus (~108 CFU) by oral gavage three times on alternate days. H. hepaticus–infected mice were sacrificed 8–10 wk after infection.

In vivo antibody treatment.

To block IL-1β activity in vivo, H. hepaticus–infected 129SvEv Rag2−/− mice were injected i.p. with 1 mg αIL-1β–blocking mAb (αIL-1β) or 1 mg isotype control mAb from the day of the first inoculation with H. hepaticus, and treatment repeated weekly for the duration of the experiment.

Induction of colitis with naive CD4+CD45RBHi T Cells.

Naive CD4+CD45RBHi T cells were purified (>98%) from spleens of C57BL/6, C57BL/6 Il1r1−/−, IL23r−/−, or Csf2−/− mice via FACS sorting, as previously described (Izcue et al., 2008). In brief, single-cell suspensions were depleted of CD8+, MHC class II+, Mac-1+, and B220+ cells by negative selection using a panel of rat monoclonal antibodies, followed by sheep anti–rat–coated Dynabeads (Invitrogen). After staining with APC-conjugated αCD4, PE-conjugated αCD25, and FITC–αCD45RB, naive CD4+CD45RBHi T cells were purified by cell sorting with a cell sorter (MoFlo; Dako). Naive T cell suspensions were washed in sterile PBS, and age- and sex-matched C57BL/6 Rag1−/− recipient mice received 4 × 105 CD4+CD45RBHi T cells by i.p. injection. For co-transfer experiments, 1:1 mixtures of CD45.2+ Il23r−/− and CD45.1+ WT CD4+CD45RBHi T cells were injected i.p. (total cell number = 4 × 105). Mice were sacrificed when symptoms of clinical disease (weight loss and/or diarrhea) developed in control groups, ~5–8 wk after transfer of naive CD4+ T cells, unless otherwise indicated. For mice sacrificed 2 wk after transfer, 2 × 106 CD4+CD45RBHi T cells were transferred per mouse.

Assessment of intestinal inflammation.

Samples of cecum and proximal, mid, and distal colon were prepared as previously described (Izcue et al., 2008), and inflammation was graded according to the following scoring system. Each sample was graded semiquantitatively from zero to three for four criteria: (1) degree of epithelial hyperplasia and goblet cell depletion; (2) leukocyte infiltration in the lamina propria; (3) area of tissue affected; and (4) the presence of markers of severe inflammation such as crypt abscesses, submucosal inflammation, and ulcers. Scores for each criterion were added to give an overall inflammation score for each sample of 0–12. Scores from proximal, mid, and distal colon were averaged to obtain inflammation scores for the colon. Sections were scored in a blinded fashion to avoid bias.

Isolation of leukocyte subpopulations and FACS.

Cell suspensions from spleen, liver, MLN, and the lamina propria were prepared as described previously (Buonocore et al., 2010). Cells were washed, incubated with anti-Fc receptor (αCD16/32), and stained for flow cytometric analysis using combinations of the following antibodies: PeCy7-conjugated αCD4 and PerCP-Cy5.5-conjugated αTCR-β (T cells) and FITC-conjugated αCD45.2, αCD11b conjugated to PE, and Gr1 conjugated to PerCP-Cy5.5 (innate cells). Intracellular staining was performed as previously described (Ahern et al., 2010): cells were restimulated for 4 h with 0.1 µg/ml PMA (Sigma-Aldrich), 1 µg/ml ionomycin (Sigma-Aldrich), and 10 µg/ml Brefeldin A (Insight Biotechnology), washed, and stained for surface markers. Cells were then fixed overnight in eBioscience Fix/Perm buffer at 4°C. Cells were washed and permeabilized in permeabilization buffer (eBioscience) with 2% rat serum for 1 h at 4°C. Cells were then stained with αIL-17A conjugated to PE, αIFN-γ conjugated to APC or e450, and αKi-67 conjugated to FITC (BD) or appropriate isotype controls (BD) for 30 min at 4°C. ILCs were identified as previously described (Buonocore et al., 2010) using αThy1.2 PE-conjugated and FITC-conjugated αLy6A/E (Sca1) (both from BD Biosciences). Lineage+ cells were excluded using PerCP-Cy5.5–conjugated αCD11b, αGr1, αB220, and αCD3e. For intracellular staining of ILCs, 10 µg/ml brefeldin A (Insight Biotechnology) was added for the last 4 h of overnight cultures in complete RPMI media. Cells were then processed similarly to T cells. For analysis of colonic T cells, CD4+ TCRβ+ cells were sorted from cLPL preparations according to the expression of the surface markers CD4 and TCRβ with a cell sorter (MoFlo; Dako) and restimulated overnight with 0.1 µg/ml PMA and 1 µg/ml ionomycin.

Cell culture.

FACS sorted ILCs were cultured overnight in RPMI, 10% FCS, 100 U/ml penicillin/streptomycin, 2 mM l-glutamine, 0.05 mM β-mercaptoethanol (complete RPMI), and 10 ng/ml IL-1β. For Th17 differentiation from total CD4+ T cells, splenic CD4+ T cells were isolated from WT or Il1r1−/− mice and cultured in IMDM, 10% FCS, 100 U/ml penicillin/streptomycin, 2 mM l-glutamine, 0.05 mM β-mercaptoethanol (complete IMDM) in the presence of 2.5 ng/ml TGF-β, and 50 ng/ml IL-6 5, plus plate-bound αCD3 (2 µg/ml) and αCD28 (1 µg/ml). For Th17 differentiation from naive CD4+ T cells, naive CD4+ CD62LHi CD44low CD25 were FACS sorted from the spleen and MLN of WT C57BL/6 or Il23r−/− mice and cultured for the indicated time in complete IMDM in the presence of 200 pg/ml TGF-β, 20 ng/ml IL-6, 20 ng/ml IL-1β, 10 ng/ml IL-21, 20 ng/ml IL-23, 10 µg/ml αIFN-γ and αIL-4, and plate-bound αCD3 and αCD28 (both at 5 µg/ml).

Quantification of gene expression by qRT-PCR.

Quantitative real time PCR (qRT-PCR) was performed as previously described (Hue et al., 2006) with homogenization of frozen tissue samples performed using a FastPrep 24 homogenizer (MP Biomedicals) with lysing matrix D beads (MP Biomedicals). Primers for Hprt (Mm01545399_m1), cxcl1 (Mm04207460_m1), cxcl2 (Mm0436450_m1), cxcl5 (Mm0436451_g1), bcl2 (Mm0477631_m1), bclxl (Mm0437783_m1), Il1r1 (Mm00434237_m1), and rorc (Mm01261022_m1) were obtained from Applied Biosystems. Levels of gene expression were normalized on Hprt expression, unless otherwise indicated. In-house primer sequences are as follows: CD3, forward, 5′-TTACAGAATGTGTGAAAACTGCATTG-3′, reverse, 5′-CACCAAGAGCAAGGAAGAAGATG-3′, and probe, 5′-ACATAGGCAC­CATATCCGGCT­TTATCTTCG-3′; CCR3 forward, 5′-TGTTTACCTCAGTTCATCCACGG-3′, reverse, 5′-CAGAATGGTAATGTGAGCAGGAA-3′, and probe, 5′-TCTGCTCAACTTGGCCATCTCTGACC-3′; CCR5 forward, 5′-CATCGATTATGGTATGTCAGCACC-3′, reverse, 5′-CAGAATGGTAGTGTGAGCAGGA-3′, and probe 5′-TACCTGCTCAACCTGGCCATCTCTGA-3′; CCR6 forward, 5′-ACTCTTTGTCCTCACCCTACCG-3′, reverse, 5′-ATCCTGCAGCTCGTATTTCTTG-3′, and probe, 5′-ACGCTCCAGAACACTGACGCACAGTA-3′; CXCR6 forward, 5′-AAGCTGAGGACTCTGACAGATGTGT-3′, reverse, 5′-CCAAAAGGGCAGAGTACAGACAA-3′, and probe, 5′-CTGCTGAACTTGCCCCTGGCTGAC-3′; IL-23R forward, 5′-CCATCTGGATGATATAGTGATACCTTCT-3′, reverse, 5′-ATGGTCTTGGGTACAGTATCGTTTG-3′, and probe, 5′-CGTCCATCATTTCCAGGGCTCACACT-3′ (Ahern et al., 2010). Amplification was performed using TaqMan Fast Universal PCR Master Mix (Applied Biosystems).

Apoptosis assay.

For in vitro assessment of apoptosis, total splenocytes from C57BL/6 or Il1r1−/− mice were depleted of CD8+, MHC class II+, Mac-1+, and B220+ cells by negative selection using sheep anti–rat–coated Dynabeads (Invitrogen; purity ≥82%). Enriched CD4+ cells were cultured for 3 d with 2.5 µg/ml or 10 µg/ml each of plate-bound αCD3 and αCD28 (eBioscience). APC anti–Annexin-V antibody and 7-Aminoactinomycin (7AAD; eBioscience) were used for apoptosis assessment. All cells were acquired on a FACSCalibur (BD) or on a CyAn ADP flow cytometer (Beckman Coulter), and analysis performed using FlowJo (Tree Star) software.

Cytokine detection.

For cytokine detection, colonic lamina propria cells we cultured overnight in complete RPMI media. IL-6, IFN-γ, IL-17, TNF, and IL-1β levels in culture supernatants were measured using FlowCytomix Bead-based assay (eBioscience) and cytokine concentration was normalized to cell number. To assess innate lymphoid cell function, colonic lamina propria cells were cultured with or without recombinant IL-23 (10 ng/ml; R&D) overnight, and IL-17 and IFN-γ were measured in the supernatants as above. Organ explants were prepared as previously described (Hue et al., 2006) and cultured overnight in complete RPMI media. IL-1β levels in the supernatants were determined by Bio-Plex Cytokine assay (Bio-Rad Laboratories), and concentrations were normalized to the weight of the explants.

Statistics.

The nonparametric Mann-Whitney test was used for assessment of statistical significance of in vivo experiments. The Student’s t test was used to assess the significance of in vitro experiments. Weight curves were compared using two-way ANOVA. Data were considered significant when P < 0.05.

Acknowledgments

We thank Nigel Rust and Helen Ferry for cell sorting, Richard Stillion for histology and the staff at University of Oxford for excellent animal care; Michael Barnes for critically reading the manuscript; Philip Ahern, Sofia Buonocore, Sofia Nordlander, George Song-Zhao, Naren Srinivasan, and Rose Szabady for technical help and support.

This work was supported by the Wellcome Trust (Career Development Fellowship to K.J. Maloy, Investigator Award to F. Powrie, PhD studentships to O.J. Harrison and C. Schiering) and the Edward Penley Abraham Trust (PhD studentship to M. Coccia).

The authors have no conflicting financial interests.

Footnotes

Abbreviations used:

7AAD
7-aminoactinomycin
CD
Crohn’s disease
cLPL
colonic lamina propria leukocyte
DSS
dextran sulfate sodium
EAE
experimental autoimmune encephalomyelitis
IBD
inflammatory bowel disease
ILC
innate lymphoid cell
MLN
mesenteric lymph node
n/a
nothing added
ND
not detectable
UC
ulcerative colitis

References

  • Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., Sallusto F. 2007. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8:942–949 10.1038/ni1496 [PubMed] [Cross Ref]
  • Ahern P.P., Schiering C., Buonocore S., McGeachy M.J., Cua D.J., Maloy K.J., Powrie F. 2010. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity. 33:279–288 10.1016/j.immuni.2010.08.010 [PMC free article] [PubMed] [Cross Ref]
  • Aksentijevich I., Masters S.L., Ferguson P.J., Dancey P., Frenkel J., van Royen-Kerkhoff A., Laxer R., Tedgård U., Cowen E.W., Pham T.H., et al. 2009. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 360:2426–2437 10.1056/NEJMoa0807865 [PMC free article] [PubMed] [Cross Ref]
  • Asquith M., Powrie F. 2010. An innately dangerous balancing act: intestinal homeostasis, inflammation, and colitis-associated cancer. J. Exp. Med. 207:1573–1577 10.1084/jem.20101330 [PMC free article] [PubMed] [Cross Ref]
  • Asquith M.J., Boulard O., Powrie F., Maloy K.J. 2010. Pathogenic and protective roles of MyD88 in leukocytes and epithelial cells in mouse models of inflammatory bowel disease. Gastroenterology. 139:519–529: 529: e1–e2 10.1053/j.gastro.2010.04.045 [PMC free article] [PubMed] [Cross Ref]
  • Atarashi K., Nishimura J., Shima T., Umesaki Y., Yamamoto M., Onoue M., Yagita H., Ishii N., Evans R., Honda K., Takeda K. 2008. ATP drives lamina propria T(H)17 cell differentiation. Nature. 455:808–812 10.1038/nature07240 [PubMed] [Cross Ref]
  • Baumgart D.C., Sandborn W.J. 2007. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 369:1641–1657 10.1016/S0140-6736(07)60751-X [PubMed] [Cross Ref]
  • Ben-Sasson S.Z., Hu-Li J., Quiel J., Cauchetaux S., Ratner M., Shapira I., Dinarello C.A., Paul W.E. 2009. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc. Natl. Acad. Sci. USA. 106:7119–7124 10.1073/pnas.0902745106 [PMC free article] [PubMed] [Cross Ref]
  • Boulard O., Kirchberger S., Royston D.J., Maloy K.J., Powrie F.M. 2012. Identification of a genetic locus controlling bacteria-driven colitis and associated cancer through effects on innate inflammation. J. Exp. Med. 209:1309–1324 10.1084/jem.20120239 [PMC free article] [PubMed] [Cross Ref]
  • Brydges S.D., Mueller J.L., McGeough M.D., Pena C.A., Misaghi A., Gandhi C., Putnam C.D., Boyle D.L., Firestein G.S., Horner A.A., et al. 2009. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity. 30:875–887 10.1016/j.immuni.2009.05.005 [PMC free article] [PubMed] [Cross Ref]
  • Buonocore S., Ahern P.P., Uhlig H.H., Ivanov I.I., Littman D.R., Maloy K.J., Powrie F. 2010. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature. 464:1371–1375 10.1038/nature08949 [PMC free article] [PubMed] [Cross Ref]
  • Calkins C.M., Bensard D.D., Shames B.D., Pulido E.J., Abraham E., Fernandez N., Meng X., Dinarello C.A., McIntyre R.C., Jr 2002. IL-1 regulates in vivo C-X-C chemokine induction and neutrophil sequestration following endotoxemia. J. Endotoxin Res. 8:59–67 [PubMed]
  • Casini-Raggi V., Kam L., Chong Y.J., Fiocchi C., Pizarro T.T., Cominelli F. 1995. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J. Immunol. 154:2434–2440 [PubMed]
  • Cella M., Fuchs A., Vermi W., Facchetti F., Otero K., Lennerz J.K., Doherty J.M., Mills J.C., Colonna M. 2009. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature. 457:722–725 10.1038/nature07537 [PMC free article] [PubMed] [Cross Ref]
  • Cella M., Otero K., Colonna M. 2010. Expansion of human NK-22 cells with IL-7, IL-2, and IL-1beta reveals intrinsic functional plasticity. Proc. Natl. Acad. Sci. USA. 107:10961–10966 10.1073/pnas.1005641107 [PMC free article] [PubMed] [Cross Ref]
  • Chaudhry A., Rudra D., Treuting P., Samstein R.M., Liang Y., Kas A., Rudensky A.Y. 2009. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science. 326:986–991 10.1126/science.1172702 [PubMed] [Cross Ref]
  • Chung Y., Chang S.H., Martinez G.J., Yang X.O., Nurieva R., Kang H.S., Ma L., Watowich S.S., Jetten A.M., Tian Q., Dong C. 2009. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity. 30:576–587 10.1016/j.immuni.2009.02.007 [PMC free article] [PubMed] [Cross Ref]
  • Codarri L., Gyülvészi G., Tosevski V., Hesske L., Fontana A., Magnenat L., Suter T., Becher B. 2011. RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 12:560–567 10.1038/ni.2027 [PubMed] [Cross Ref]
  • Cominelli F., Nast C.C., Clark B.D., Schindler R., Lierena R., Eysselein V.E., Thompson R.C., Dinarello C.A. 1990. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J. Clin. Invest. 86:972–980 10.1172/JCI114799 [PMC free article] [PubMed] [Cross Ref]
  • Cominelli F., Nast C.C., Duchini A., Lee M. 1992. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology. 103:65–71 [PubMed]
  • Cupedo T., Crellin N.K., Papazian N., Rombouts E.J., Weijer K., Grogan J.L., Fibbe W.E., Cornelissen J.J., Spits H. 2009. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat. Immunol. 10:66–74 10.1038/ni.1668 [PubMed] [Cross Ref]
  • Dinarello C.A. 1996. Biologic basis for interleukin-1 in disease. Blood. 87:2095–2147 [PubMed]
  • Dinarello C.A. 2009. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27:519–550 10.1146/annurev.immunol.021908.132612 [PubMed] [Cross Ref]
  • El-Behi M., Ciric B., Dai H., Yan Y., Cullimore M., Safavi F., Zhang G.X., Dittel B.N., Rostami A. 2011. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 12:568–575 10.1038/ni.2031 [PMC free article] [PubMed] [Cross Ref]
  • Erdman S.E., Poutahidis T., Tomczak M., Rogers A.B., Cormier K., Plank B., Horwitz B.H., Fox J.G. 2003. CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am. J. Pathol. 162:691–702 10.1016/S0002-9440(10)63863-1 [PMC free article] [PubMed] [Cross Ref]
  • Fujino S., Andoh A., Bamba S., Ogawa A., Hata K., Araki Y., Bamba T., Fujiyama Y. 2003. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 52:65–70 10.1136/gut.52.1.65 [PMC free article] [PubMed] [Cross Ref]
  • Fukata M., Breglio K., Chen A., Vamadevan A.S., Goo T., Hsu D., Conduah D., Xu R., Abreu M.T. 2008. The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease. J. Immunol. 180:1886–1894 [PMC free article] [PubMed]
  • Gabay C., Lamacchia C., Palmer G. 2010. IL-1 pathways in inflammation and human diseases. Nat. Rev. Rheumatol. 6:232–241 10.1038/nrrheum.2010.4 [PubMed] [Cross Ref]
  • Ghoreschi K., Laurence A., Yang X.P., Tato C.M., McGeachy M.J., Konkel J.E., Ramos H.L., Wei L., Davidson T.S., Bouladoux N., et al. 2010. Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling. Nature. 467:967–971 10.1038/nature09447 [PMC free article] [PubMed] [Cross Ref]
  • Guo L., Wei G., Zhu J., Liao W., Leonard W.J., Zhao K., Paul W. 2009. IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc. Natl. Acad. Sci. USA. 106:13463–13468 10.1073/pnas.0906988106 [PMC free article] [PubMed] [Cross Ref]
  • Horai R., Saijo S., Tanioka H., Nakae S., Sudo K., Okahara A., Ikuse T., Asano M., Iwakura Y. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191:313–320 10.1084/jem.191.2.313 [PMC free article] [PubMed] [Cross Ref]
  • Hue S., Ahern P., Buonocore S., Kullberg M.C., Cua D.J., McKenzie B.S., Powrie F., Maloy K.J. 2006. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med. 203:2473–2483 10.1084/jem.20061099 [PMC free article] [PubMed] [Cross Ref]
  • Hughes T., Becknell B., Freud A.G., McClory S., Briercheck E., Yu J., Mao C., Giovenzana C., Nuovo G., Wei L., et al. 2010. Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. Immunity. 32:803–814 10.1016/j.immuni.2010.06.007 [PMC free article] [PubMed] [Cross Ref]
  • Ivanov I.I., Atarashi K., Manel N., Brodie E.L., Shima T., Karaoz U., Wei D., Goldfarb K.C., Santee C.A., Lynch S.V., et al. 2009. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 139:485–498 10.1016/j.cell.2009.09.033 [PMC free article] [PubMed] [Cross Ref]
  • Izcue A., Coombes J.L., Powrie F. 2006. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol. Rev. 212:256–271 10.1111/j.0105-2896.2006.00423.x [PubMed] [Cross Ref]
  • Izcue A., Hue S., Buonocore S., Arancibia-Cárcamo C.V., Ahern P.P., Iwakura Y., Maloy K.J., Powrie F. 2008. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity. 28:559–570 10.1016/j.immuni.2008.02.019 [PMC free article] [PubMed] [Cross Ref]
  • Kaser A., Zeissig S., Blumberg R.S. 2010. Inflammatory bowel disease. Annu. Rev. Immunol. 28:573–621 10.1146/annurev-immunol-030409-101225 [PubMed] [Cross Ref]
  • Kullberg M.C., Jankovic D., Feng C.G., Hue S., Gorelick P.L., McKenzie B.S., Cua D.J., Powrie F., Cheever A.W., Maloy K.J., Sher A. 2006. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J. Exp. Med. 203:2485–2494 10.1084/jem.20061082 [PMC free article] [PubMed] [Cross Ref]
  • Lamacchia C., Palmer G., Seemayer C.A., Talabot-Ayer D., Gabay C. 2010. Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist. Arthritis Rheum. 62:452–462 [PubMed]
  • Leppkes M., Becker C., Ivanov I.I., Hirth S., Wirtz S., Neufert C., Pouly S., Murphy A.J., Valenzuela D.M., Yancopoulos G.D., et al. 2009. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology. 136:257–267 10.1053/j.gastro.2008.10.018 [PubMed] [Cross Ref]
  • Ligumsky M., Simon P.L., Karmeli F., Rachmilewitz D. 1990. Role of interleukin 1 in inflammatory bowel disease—enhanced production during active disease. Gut. 31:686–689 10.1136/gut.31.6.686 [PMC free article] [PubMed] [Cross Ref]
  • Littman D.R., Rudensky A.Y. 2010. Th17 and regulatory T cells in mediating and restraining inflammation. Cell. 140:845–858 10.1016/j.cell.2010.02.021 [PubMed] [Cross Ref]
  • Ludwiczek O., Vannier E., Borggraefe I., Kaser A., Siegmund B., Dinarello C.A., Tilg H. 2004. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin. Exp. Immunol. 138:323–329 10.1111/j.1365-2249.2004.02599.x [PMC free article] [PubMed] [Cross Ref]
  • Maeda S., Hsu L.C., Liu H., Bankston L.A., Iimura M., Kagnoff M.F., Eckmann L., Karin M. 2005. Nod2 mutation in Crohn’s disease potentiates NF-kappaB activity and IL-1beta processing. Science. 307:734–738 10.1126/science.1103685 [PubMed] [Cross Ref]
  • Mahida Y.R., Wu K., Jewell D.P. 1989. Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn’s disease. Gut. 30:835–838 10.1136/gut.30.6.835 [PMC free article] [PubMed] [Cross Ref]
  • Maloy K.J., Salaun L., Cahill R., Dougan G., Saunders N.J., Powrie F. 2003. CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J. Exp. Med. 197:111–119 10.1084/jem.20021345 [PMC free article] [PubMed] [Cross Ref]
  • Martinon F., Mayor A., Tschopp J. 2009. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27:229–265 10.1146/annurev.immunol.021908.132715 [PubMed] [Cross Ref]
  • McAlindon M.E., Hawkey C.J., Mahida Y.R. 1998. Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease. Gut. 42:214–219 10.1136/gut.42.2.214 [PMC free article] [PubMed] [Cross Ref]
  • McCall R.D., Haskill S., Zimmermann E.M., Lund P.K., Thompson R.C., Sartor R.B. 1994. Tissue interleukin 1 and interleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats. Gastroenterology. 106:960–972 [PubMed]
  • Melmed G.Y., Targan S.R. 2010. Future biologic targets for IBD: potentials and pitfalls. Nat. Rev. Gastroenterol. Hepatol. 7:110–117 10.1038/nrgastro.2009.218 [PubMed] [Cross Ref]
  • Meng G., Zhang F., Fuss I., In briefani A., Strober W. 2009. A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity. 30:860–874 10.1016/j.immuni.2009.04.012 [PMC free article] [PubMed] [Cross Ref]
  • Müller A.J., Hoffmann C., Galle M., Van Den Broeke A., Heikenwalder M., Falter L., Misselwitz B., Kremer M., Beyaert R., Hardt W.D. 2009. The S. Typhimurium effector SopE induces caspase-1 activation in stromal cells to initiate gut inflammation. Cell Host Microbe. 6:125–136 10.1016/j.chom.2009.07.007 [PubMed] [Cross Ref]
  • Ng J., Hirota S.A., Gross O., Li Y., Ulke-Lemee A., Potentier M.S., Schenck L.P., Vilaysane A., Seamone M.E., Feng H., et al. 2010. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology. 139:542–552: 552: e1–e3 10.1053/j.gastro.2010.04.005 [PubMed] [Cross Ref]
  • Nielsen O.H., Kirman I., Rüdiger N., Hendel J., Vainer B. 2003. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand. J. Gastroenterol. 38:180–185 10.1080/00365520310000672 [PubMed] [Cross Ref]
  • O’Connor W., Jr, Kamanaka M., Booth C.J., Town T., Nakae S., Iwakura Y., Kolls J.K., Flavell R.A. 2009. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat. Immunol. 10:603–609 10.1038/ni.1736 [PMC free article] [PubMed] [Cross Ref]
  • Ogawa A., Andoh A., Araki Y., Bamba T., Fujiyama Y. 2004. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin. Immunol. 110:55–62 10.1016/j.clim.2003.09.013 [PubMed] [Cross Ref]
  • Okayasu I., Hatakeyama S., Yamada M., Ohkusa T., Inagaki Y., Nakaya R. 1990. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 98:694–702 [PubMed]
  • Plantinga T.S., Crisan T.O., Oosting M., van de Veerdonk F.L., de Jong D.J., Philpott D.J., van der Meer J.W., Girardin S.E., Joosten L.A., Netea M.G. 2011. Crohn’s disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut. 60:1229–1235 10.1136/gut.2010.228908 [PubMed] [Cross Ref]
  • Powrie F., Leach M.W., Mauze S., Caddle L.B., Coffman R.L. 1993. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int. Immunol. 5:1461–1471 10.1093/intimm/5.11.1461 [PubMed] [Cross Ref]
  • Reddy S., Jia S., Geoffrey R., Lorier R., Suchi M., Broeckel U., Hessner M.J., Verbsky J. 2009. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N. Engl. J. Med. 360:2438–2444 10.1056/NEJMoa0809568 [PMC free article] [PubMed] [Cross Ref]
  • Reinecker H.C., Steffen M., Witthoeft T., Pflueger I., Schreiber S., MacDermott R.P., Raedler A. 1993. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin. Exp. Immunol. 94:174–181 10.1111/j.1365-2249.1993.tb05997.x [PMC free article] [PubMed] [Cross Ref]
  • Reynders A., Yessaad N., Vu Manh T.P., Dalod M., Fenis A., Aubry C., Nikitas G., Escalière B., Renauld J.C., Dussurget O., et al. 2011. Identity, regulation and in vivo function of gut NKp46+RORγt+ and NKp46+RORγt- lymphoid cells. EMBO J. 30:2934–2947 10.1038/emboj.2011.201 [PMC free article] [PubMed] [Cross Ref]
  • Saitoh T., Fujita N., Jang M.H., Uematsu S., Yang B.G., Satoh T., Omori H., Noda T., Yamamoto N., Komatsu M., et al. 2008. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature. 456:264–268 10.1038/nature07383 [PubMed] [Cross Ref]
  • Satsangi J., Wolstencroft R.A., Cason J., Ainley C.C., Dumonde D.C., Thompson R.P. 1987. Interleukin 1 in Crohn’s disease. Clin. Exp. Immunol. 67:594–605 [PMC free article] [PubMed]
  • Shaw M.H., Kamada N., Kim Y.-G., Núñez G. 2012. Microbiota-induced IL-1β, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine. J. Exp. Med. 209:251–258 10.1084/jem.20111703 [PMC free article] [PubMed] [Cross Ref]
  • Siegmund B., Lehr H.A., Fantuzzi G., Dinarello C.A. 2001. IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc. Natl. Acad. Sci. USA. 98:13249–13254 10.1073/pnas.231473998 [PMC free article] [PubMed] [Cross Ref]
  • Sims J.E., Smith D.E. 2010. The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 10:89–102 10.1038/nri2691 [PubMed] [Cross Ref]
  • Sutton C., Brereton C., Keogh B., Mills K.H., Lavelle E.C. 2006. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 203:1685–1691 10.1084/jem.20060285 [PMC free article] [PubMed] [Cross Ref]
  • Sutton C.E., Lalor S.J., Sweeney C.M., Brereton C.F., Lavelle E.C., Mills K.H. 2009. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity. 31:331–341 10.1016/j.immuni.2009.08.001 [PubMed] [Cross Ref]
  • Thomas T.K., Will P.C., Srivastava A., Wilson C.L., Harbison M., Little J., Chesonis R.S., Pignatello M., Schmolze D., Symington J., et al. 1991. Evaluation of an interleukin-1 receptor antagonist in the rat acetic acid-induced colitis model. Agents Actions. 34:187–190 10.1007/BF01993274 [PubMed] [Cross Ref]
  • Thornberry N.A., Bull H.G., Calaycay J.R., Chapman K.T., Howard A.D., Kostura M.J., Miller D.K., Molineaux S.M., Weidner J.R., Aunins J., et al. 1992. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 356:768–774 10.1038/356768a0 [PubMed] [Cross Ref]
  • Tomita T., Kanai T., Fujii T., Nemoto Y., Okamoto R., Tsuchiya K., Totsuka T., Sakamoto N., Akira S., Watanabe M. 2008. MyD88-dependent pathway in T cells directly modulates the expansion of colitogenic CD4+ T cells in chronic colitis. J. Immunol. 180:5291–5299 [PubMed]
  • Young V.B., Knox K.A., Pratt J.S., Cortez J.S., Mansfield L.S., Rogers A.B., Fox J.G., Schauer D.B. 2004. In vitro and in vivo characterization of Helicobacter hepaticus cytolethal distending toxin mutants. Infect. Immun. 72:2521–2527 10.1128/IAI.72.5.2521-2527.2004 [PMC free article] [PubMed] [Cross Ref]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...